Biological Psychiatry
February 1, 2023
Anne Maj van der Velden, Jacqueline Scholl, Else-Marie Elmholdt et al.
Depression is a leading cause of disability worldwide and its prevalence is on the rise. One of the most debilitating aspects of depression is the dominance and persistence of depressive rumination, a state of mind that is linked to onset and recurrence of depression. Mindfulness meditation trains adaptive attention regulation and present-moment embodied awareness, skills that may be...
Neuropharmacology
February 1, 2023
Shigeyuki Chaki, Mai Watanabe
The efficacy of currently available medications for depression is unsatisfactory, and that has spurred the development of novel antidepressants based on a hypothesis other than the monoamine hypothesis. Recent studies have revealed the importance of the glutamatergic system as a drug target for depression, and the validity of this hypothesis has been underpinned by the discovery of the...
Journal of Affective Disorders
February 1, 2023
Kwonmok Ko, Emma I Kopra, Anthony J. Cleare et al.
144 citations
Psychedelic therapy shows promise for Major Depressive Disorder, especially when treatment-resistant, as well as life-threatening illness distress. The objective of this systematic review, inclusive of meta-analysis, is to examine recent clinical research on the therapeutic effects of classic psychedelics on depressive symptoms. Fourteen psychedelic therapy studies, utilising psilocybin,...
Biological Psychiatry
February 1, 2023
Friederike Holze, Peter Gasser, Felix Müller et al.
294 citations
This study aimed to investigate the efficacy and safety of lysergic acid diethylamide (LSD)-assisted therapy in patients who experienced anxiety with or without association with a life-threatening illness. The study is an investigator-initiated 2-center trial that used a double-blind, placebo-controlled, 2-period, random-order, crossover design with 2 sessions with either oral LSD (200 μg) or...
ACS Chemical Neuroscience
February 1, 2023
Lindsay P. Cameron, Seona D Patel, Maxemiliano V. Vargas et al.
113 citations
Psychedelic compounds have displayed antidepressant potential in both humans and rodents. Despite their promise, psychedelics can induce undesired effects that pose safety concerns and limit their clinical scalability. The rational development of optimized psychedelic-related medicines will require a full mechanistic understanding of how these molecules produce therapeutic effects. While the...
Faṣlnāmah-i Farhang Mushavirah va Ravān/Darmānī
January 30, 2023
Fatemeh Eslahi Farshami, Ali Asghar Asgharnejad Farid, Khadijeh Abolmoali Alhosseini et al.
The present study was conducted to determine the effectiveness of mindfulness training based metaphors of Molavi's Masnavi on components of psychological capital among depressed female students. In this study, to extract the metaphors of Molavi's Masnavi, directional qualitative content analysis and quantitative content analysis were used with MAXQDA software. The identified codes were...
BMC Psychology
January 12, 2023
Jennifer E S Beauchamp, Anjail Sharrief, Alejandro Chaoul et al.
Depressive symptoms are a significant psychological complication of stroke, impacting both survivors and informal caregivers of survivors. Randomized controlled trials are needed to determine optimal non-pharmacological strategies to prevent or ameliorate depressive symptoms in stroke survivors and their informal caregivers. A prospective, randomized, parallel-group, single-center, feasibility...
Annals of Pharmacotherapy
January 12, 2023
C Michael White, Nissen Weisman, Joseph Dalo
18 citations
Objective: To assess the role of psychedelics in the treatment of anxiety or depression among patients with cancer. Data Sources: PubMed search from inception to March 11, 2022, using the terms anxiety, depression, psychedelics, psilocybin, lysergic acid, methylenedioxymethamphetamine, or ayahuasca. Study Selection and Data Extraction: Studies assessing patients with cancer receiving...
Frontiers in Psychiatry
January 10, 2023
Jennifer Warner-Schmidt, Christopher Pittenger, Martin Stogniew et al.
11 citations
Introduction Selective serotonin reuptake inhibitor (SSRI) antidepressants represent first-line pharmacological treatment for a variety of neuropsychiatric illnesses, including major depressive disorder (MDD), anxiety, and post-traumatic stress disorder (PTSD), which show high rates of comorbidity. SSRIs have a delayed onset of action. Most patients do not show significant effects until 4–8...
Clinical Gerontologist
2023
Jay Kayser, Rita Xiaochen Hu, Danielle Rosenscruggs et al.
Chronic medical conditions can increase the likelihood of experiencing psychological distress and mental health problems among older adults. Mindfulness interventions (MIs) are evidence-based treatment approaches that can improve psychological outcomes. This systematic literature review examines MI studies that focused on older adults (≥60 years old) with chronic health conditions. Five...